• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma.

作者信息

Acanda De La Rocha Arlet M, Fader Maggie, Coats Ebony R, Espinal Paula S, Berrios Vanessa, Saghira Cima, Sotto Ileana, Shakya Rojesh, Janvier Michelin, Khatib Ziad, Abdella Haneen, Bittle Mathew, Andrade-Feraud Cristina M, Guilarte Tomás R, McCafferty-Fernandez Jennifer, Salyakina Daria, Azzam Diana J

机构信息

Department of Environmental Health Sciences, Robert Stempel College of Public Health & Social Work, Florida International University, Miami, FL.

Personalized Medicine Initiative, Nicklaus Children's Hospital, Miami, FL.

出版信息

JCO Precis Oncol. 2021 Oct 27;5. doi: 10.1200/PO.20.00438. eCollection 2021.

DOI:10.1200/PO.20.00438
PMID:34738048
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8563073/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/6b15c8333a02/po-5-po.20.00438-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/9084047a7d52/po-5-po.20.00438-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/397c28f41cba/po-5-po.20.00438-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/6b15c8333a02/po-5-po.20.00438-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/9084047a7d52/po-5-po.20.00438-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/397c28f41cba/po-5-po.20.00438-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/3600/8563073/6b15c8333a02/po-5-po.20.00438-g004.jpg

相似文献

1
Clinical Utility of Functional Precision Medicine in the Management of Recurrent/Relapsed Childhood Rhabdomyosarcoma.功能精准医学在儿童复发性/难治性横纹肌肉瘤管理中的临床应用
JCO Precis Oncol. 2021 Oct 27;5. doi: 10.1200/PO.20.00438. eCollection 2021.
2
Cisplatin and doxorubicin for locally recurrent and metastatic childhood rhabdomyosarcoma.顺铂和阿霉素用于儿童局部复发性和转移性横纹肌肉瘤
Chemioterapia. 1984 Aug;3(4):207-10.
3
A combinatorial drug screen in PDX-derived primary rhabdomyosarcoma cells identifies the NOXA - BCL-XL/MCL-1 balance as target for re-sensitization to first-line therapy in recurrent tumors.在 PDX 衍生的原发性横纹肌肉瘤细胞中的组合药物筛选确定了 NOXA-BCL-XL/MCL-1 平衡作为重新敏感化一线治疗复发性肿瘤的靶点。
Neoplasia. 2021 Sep;23(9):929-938. doi: 10.1016/j.neo.2021.07.001. Epub 2021 Jul 27.
4
Positron emission tomography (PET) evaluation after initial chemotherapy and radiation therapy predicts local control in rhabdomyosarcoma.正电子发射断层扫描（PET）在初始化疗和放疗后的评估可预测横纹肌肉瘤的局部控制。
Int J Radiat Oncol Biol Phys. 2012 Nov 15;84(4):996-1002. doi: 10.1016/j.ijrobp.2012.01.077. Epub 2012 May 5.
5
Intra-arterial chemotherapy for rhabdomyosarcoma.横纹肌肉瘤的动脉内化疗
Pediatr Hematol Oncol. 2021 May;38(4):391-396. doi: 10.1080/08880018.2020.1871138. Epub 2021 Jan 13.
6
Reasonable Attempt at a Randomized Trial in Relapsed Rhabdomyosarcoma.复发性横纹肌肉瘤随机试验的合理尝试
J Clin Oncol. 2021 Sep 20;39(27):2977-2978. doi: 10.1200/JCO.21.01631. Epub 2021 Aug 12.
7
Primary cardiac rhabdomyosarcoma exhibiting transient and pronounced regression with chemotherapy.原发性心脏横纹肌肉瘤经化疗后出现短暂且显著的消退。
Am Heart J. 1990 Dec;120(6 Pt 1):1458-60. doi: 10.1016/0002-8703(90)90267-2.
8
Relapse after localized rhabdomyosarcoma: Evaluation of the efficacy of second-line chemotherapy.局限性横纹肌肉瘤复发：二线化疗疗效评估
Pediatr Blood Cancer. 2015 Nov;62(11):1935-41. doi: 10.1002/pbc.25622. Epub 2015 Jul 6.
9
The treatment of orbital rhabdomyosarcoma with irradiation and chemotherapy.采用放疗和化疗治疗眼眶横纹肌肉瘤。
Ophthalmology. 1979 Jul;86(7):1330-5. doi: 10.1016/s0161-6420(79)35394-5.
10
Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.利用横纹肌肉瘤患者来源的异种移植模型来研究精准医学方法并模拟获得性耐药。
Pediatr Blood Cancer. 2014 Sep;61(9):1570-7. doi: 10.1002/pbc.25039. Epub 2014 Mar 31.

引用本文的文献

1
Case Report: Application of drug sensitivity testing to identify personalized treatment options for an adolescent with diffuse midline glioma.病例报告：应用药敏试验为一名弥漫性中线胶质瘤青少年患者确定个性化治疗方案。
Front Oncol. 2025 Aug 7;15:1606575. doi: 10.3389/fonc.2025.1606575. eCollection 2025.
2
Integrated molecular and functional characterization of the intrinsic apoptotic machinery identifies therapeutic vulnerabilities in glioma.整合内在凋亡机制的分子和功能特征，鉴定神经胶质瘤治疗的脆弱性。
Nat Commun. 2024 Nov 21;15(1):10089. doi: 10.1038/s41467-024-54138-9.
3
Feasibility of functional precision medicine for guiding treatment of relapsed or refractory pediatric cancers.

本文引用的文献

1
Genomic Classification and Clinical Outcome in Rhabdomyosarcoma: A Report From an International Consortium.横纹肌肉瘤的基因组分类和临床结局：国际联盟的报告
J Clin Oncol. 2021 Sep 10;39(26):2859-2871. doi: 10.1200/JCO.20.03060. Epub 2021 Jun 24.
2
Ovarian Cancer Treatment Stratification Using Drug Sensitivity Testing.基于药物敏感性测试的卵巢癌治疗分层。
Anticancer Res. 2019 Aug;39(8):4023-4030. doi: 10.21873/anticanres.13558.
3
Drug sensitivity testing on patient-derived sarcoma cells predicts patient response to treatment and identifies c-Sarc inhibitors as active drugs for translocation sarcomas.
功能精准医学指导复发或难治性儿科癌症治疗的可行性。
Nat Med. 2024 Apr;30(4):990-1000. doi: 10.1038/s41591-024-02848-4. Epub 2024 Apr 11.
4
Drug sensitivity profiling of 3D tumor tissue cultures in the pediatric precision oncology program INFORM.儿科精准肿瘤学项目INFORM中3D肿瘤组织培养的药物敏感性分析。
NPJ Precis Oncol. 2022 Dec 27;6(1):94. doi: 10.1038/s41698-022-00335-y.
5
Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.间质瘤类器官模型重现横纹肌肉瘤亚型。
EMBO Mol Med. 2022 Oct 10;14(10):e16001. doi: 10.15252/emmm.202216001. Epub 2022 Aug 2.
对患者来源的肉瘤细胞进行药物敏感性测试可预测患者对治疗的反应，并确定 c-Sarc 抑制剂为易位肉瘤的有效药物。
Br J Cancer. 2019 Feb;120(4):435-443. doi: 10.1038/s41416-018-0359-4. Epub 2019 Feb 12.
4
MYOD1-mutant spindle cell and sclerosing rhabdomyosarcoma: an aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification.MYOD1 突变性梭形细胞和硬化性横纹肌肉瘤：一种侵袭性亚型，与年龄无关。对分子分类和危险分层的重新评估。
Mod Pathol. 2019 Jan;32(1):27-36. doi: 10.1038/s41379-018-0120-9. Epub 2018 Sep 4.
5
Ex-vivo sensitivity profiling to guide clinical decision making in acute myeloid leukemia: A pilot study.急性髓系白血病的体外敏感性分析以指导临床决策：一项试点研究。
Leuk Res. 2018 Jan;64:34-41. doi: 10.1016/j.leukres.2017.11.008. Epub 2017 Nov 11.
6
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.针对侵袭性血液系统恶性肿瘤患者的基于图像的体外药物筛选：一项单臂、开放标签试点研究的中期结果。
Lancet Haematol. 2017 Dec;4(12):e595-e606. doi: 10.1016/S2352-3026(17)30208-9. Epub 2017 Nov 15.
7
Functional precision cancer medicine-moving beyond pure genomics.功能精准癌症医学——超越纯基因组学。
Nat Med. 2017 Sep 8;23(9):1028-1035. doi: 10.1038/nm.4389.
8
VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.长春新碱、伊立替康和替莫唑胺用于复发横纹肌肉瘤儿童和青少年患者
Pediatr Blood Cancer. 2018 Jan;65(1). doi: 10.1002/pbc.26728. Epub 2017 Jul 27.
9
MYOD1 (L122R) mutations are associated with spindle cell and sclerosing rhabdomyosarcomas with aggressive clinical outcomes.MYOD1（L122R）突变与具有侵袭性临床结果的梭形细胞和硬化性横纹肌肉瘤相关。
Mod Pathol. 2016 Dec;29(12):1532-1540. doi: 10.1038/modpathol.2016.144. Epub 2016 Aug 26.
10
Clinicopathological implications of in Ewing sarcoma.尤因肉瘤中[具体内容缺失]的临床病理意义
Oncol Lett. 2016 Jun;11(6):4077-4082. doi: 10.3892/ol.2016.4521. Epub 2016 May 5.